Boston Scientific Corporation (BSX) Stock Analysis
Over the past 10 years, Boston Scientific (BSX) earnings per share (EPS) grew 118.9% a year, revenue grew 10.4% a year and free cash flow grew 26.3% a year, with an average return on invested capital (ROIC) of 5.9%. BSX stock trades at $44.39, a P/E of 13.4, below its historical average of 60.0. Analysts' average 12-month price target is $61.48 (+38.5%).
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe.
Exhibit A Growth Dossier
| Metric | 10yr | 5yr | 1yr | Grade |
|---|---|---|---|---|
| Book Value/Share GrowthBV/S | 13.2% | 8.4% | 11.8% | B+ |
| EPS GrowthEPS | 118.9% | 502.8% | 17.0% | A+ |
| Revenue GrowthRevenue | 10.4% | 15.2% | 13.5% | A- |
| Cash Flow GrowthCash Flow | 26.3% | 26.4% | 9.5% | A- |
| ROICROIC | 5.9% | 6.2% | 8.8% | C+ |
Exhibit B Valuation Ledger
- Current EPS
- $3.31
- Historical Avg P/E
- 60.0
- Future P/E (used for sticker price)
- Projected EPS (10yr)
- Sticker Price (10yr)
- Price for 15% Annual Return
- Expected Annual Return
No card required. $5/month after the trial if you keep going.
Not investment advice — a structured read of historical fundamentals, not a forecast or recommendation. Always do your own research.
Exhibit C Raw Data (last 10 years)
| Metric | Trend | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / ShareBV/S | $4.71 | $4.89 | $5.03 | $6.23 | $9.84 | $10.82 | $11.59 | $12.21 | $13.18 | $14.65 | $16.21 | $16.79 | |
| Basic EPSEPS | -$0.18 | $0.26 | $0.08 | $1.21 | $3.38 | -$0.08 | $0.69 | $0.45 | $1.08 | $1.26 | $1.96 | $3.31 | |
| RevenueRevenue | $7,477,000,000 | $8,386,000,000 | $9,048,000,000 | $9,823,000,000 | $10,735,000,000 | $9,913,000,000 | $11,888,000,000 | $12,682,000,000 | $14,240,000,000 | $16,747,000,000 | $20,074,000,000 | $20,996,000,000 | |
| Free Cash FlowCash Flow | $353,000,000 | $596,000,000 | $1,107,000,000 | $-6,000,000 | $1,375,000,000 | $1,132,000,000 | $1,316,000,000 | $914,000,000 | $1,703,000,000 | $2,645,000,000 | $3,658,000,000 | $3,625,000,000 | |
| ROIC (%)ROIC | 1.8% | 8.5% | 1.1% | 9.7% | 6.3% | 2.2% | 6.6% | 3.9% | 5.7% | 6.1% | 8.8% | — |
The exact underlying data used to compute the growth rates and grades above. The highlighted TTM column is the trailing twelve months through the most recently reported quarter.
Ticker INVESTigator Price Target
Analyst Data
Price Target
Where the stock trades today vs. the range of 12-month price targets from covering analysts.
44 firms rate it — 1 strong buy, 36 buy, 7 hold · Most recent Oct 2026
BSX Stock FAQ
What is BSX's stock price target?
The average 12-month analyst price target for BSX is $61.48, with a range of $48.00 to $100.00. That is +38.5% from the current price of $44.39.
Do analysts rate BSX a buy?
Most rate it a buy. Of 44 firms covering Boston Scientific, the ratings are 37 buy or strong buy, 7 hold and 0 sell or strong sell.
How fast is Boston Scientific growing?
Annual growth rates for BSX. EPS: 118.9% over 10 years, 502.8% over 5 years, 17.0% over 1 year. Revenue: 10.4% over 10 years, 15.2% over 5 years, 13.5% over 1 year. Free cash flow: 26.3% over 10 years, 26.4% over 5 years, 9.5% over 1 year. Book value per share: 13.2% over 10 years, 8.4% over 5 years, 11.8% over 1 year.
What is BSX's ROIC?
Boston Scientific's return on invested capital (ROIC) was 8.8% in fiscal 2025. Its 10-year average ROIC is 5.9%. ROIC above 10% is generally a sign of a business with a durable competitive advantage.
What is BSX's P/E ratio?
BSX's current P/E ratio is 13.4, compared with a historical average of 60.0. Trailing earnings per share are $3.31.
What is Boston Scientific's market cap and stock price?
BSX last traded at $44.39 as of October 19, 2026. Its 52-week range is $41.39 to $105.65. Boston Scientific has a market cap of $64.33B.
Exhibit D Related Coverage
Similar Stocks
Data as of October 19, 2026. Findings are derived from historical fundamentals — not a forecast, not advice. Cross-examine before you invest.
Grades are produced by Ticker INVESTigator's own model from public financial data and are for informational and educational purposes only. They are not investment advice or a recommendation to buy or sell any security. Do your own research.